Pfizer Inc (NYSE:PFE, ETR:PFE) looks set to open higher Monday after it revealed that its late-stage trial for a Respiratory Syncytial Virus (RSV) vaccine showed strong neutralizing responses after a single dose in adults.
The Phase 3 study tested Abrysvo against a placebo in people with immunocompromising conditions at risk for severe RSV-related lower respiratory tract disease.
Results indicated that the vaccine generated strong neutralizing responses across all age groups and was well tolerated, with a safety profile consistent with previous studies.
Pfizer plans to present these findings at an upcoming scientific conference and will submit the data to regulatory agencies for review.
Premarket, the shares were marked up 0.3%.
RSV is a common respiratory virus that usually causes mild, cold-like symptoms. However, it can be more serious, particularly in vulnerable populations.
It is the most common cause of bronchiolitis and pneumonia in children under one year of age. In severe cases, it can lead to hospitalization, especially in infants, who may experience difficulty breathing, dehydration, or require oxygen therapy.
While RSV is often associated with infants and young children, it also poses significant risks to older adults, particularly those over 65, and individuals with compromised immune systems. In older adults, RSV can exacerbate existing chronic health conditions such as asthma, chronic obstructive pulmonary disease (COPD), and heart failure.
The virus can lead to severe respiratory illness, and in some cases, it may result in death. Adults with weakened immune systems, such as those undergoing cancer treatment or those with HIV/AIDS, are also at higher risk of severe RSV infections.
Seasonal in nature, it typically occurs during the fall and winter months, aligning with other respiratory viruses like the flu.